lorundrostat
Jump to navigation
Jump to search
Indications
- refractory hypertension (investigational)[1]
Dosage
Adverse effects
- drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)
- drug adverse effects of antihypertensive agents
Mechanism of action
- aldosterone synthase inhibitor
More general terms
References
- ↑ 1.0 1.1 Laffin LJ, Rodman D, Luther JM et al Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension. The Target-HTN Randomized Clinical Trial. JAMA. 2023;330(12):1140-1150. PMID: https://pubmed.ncbi.nlm.nih.gov/37690061 PMCID: PMC10493865 Free PMC article https://jamanetwork.com/journals/jama/fullarticle/2809625
- ↑ Laffin LJ, Kopjar B, Melgaard C et al Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025 Apr 23. PMID: https://pubmed.ncbi.nlm.nih.gov/40267417 https://www.nejm.org/doi/full/10.1056/NEJMoa2501440